Tag: femoropopliteal disease

Index atherectomy interventions for claudication ‘is associated with higher’ reintervention rates...

Atherectomy use during index peripheral vascular interventions in claudicants is associated with higher reintervention rates when compared to other technologies, a newly unveiled study...

Smoking status ‘should not deter nor delay’ endovascular intervention in femoropopliteal...

Smoking does not seem to affect reocclusion rates, interval to reintervention and the total number of interventions in peripheral arterial disease (PAD) patients with...

One-year results show ‘superior’ primary patency rate for Eluvia DES compared...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...

Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception

“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons in the peripheral arteries,” findings from a systematic review...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

How to succeed in vascular surgery: A guide for the aspiring...

Disclaimer: The views expressed here do not reflect those of Mayo Clinic, the Society for Vascular Surgery, Vascular Specialist, or even the author, for...

LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...

A key theme among the late-breaking trial data presented at the recent LINC 2021 (the Leipzig Interventional Course), held digitally from Jan. 25–29, was the...